GSK-3186899

N/A

Report date: 2024/09/29 13:44:36
NME

Base Information

Drug NameGSK-3186899
Drug Alias NameDDD-853651GSK-3186899GSK899DNDi-6899
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase inhibitors
TargetsCyclin-dependent kinase
Therapy Area/IndicationsLeishmaniasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcUniversity Of Dundee
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsLeishmaniasis

Other Information

ATC CodeN/A
Related LinksN/A